CERT Stock Overview
Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CERT from our risk checks.
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.31 |
| 52 Week High | US$19.87 |
| 52 Week Low | US$10.35 |
| Beta | 1.5 |
| 11 Month Change | -11.98% |
| 3 Month Change | -17.08% |
| 1 Year Change | -21.51% |
| 33 Year Change | -68.61% |
| 5 Year Change | n/a |
| Change since IPO | -70.30% |
Recent News & Updates
Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31
Recent updates
Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price
Jul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital
Jun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?
Apr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk
Mar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)
Feb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
Jan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Dec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Oct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue
Aug 03Certara: A Story To Watch
Sep 27Certara to raise capital in secondary stock offering
Aug 12Shareholder Returns
| CERT | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 5.5% | 0.2% | 2.6% |
| 1Y | -21.5% | 3.1% | 30.5% |
Return vs Industry: CERT underperformed the US Healthcare Services industry which returned 1.8% over the past year.
Return vs Market: CERT underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| CERT volatility | |
|---|---|
| CERT Average Weekly Movement | 7.1% |
| Healthcare Services Industry Average Movement | 9.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERT's share price has been volatile over the past 3 months.
Volatility Over Time: CERT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,365 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
Certara, Inc. Fundamentals Summary
| CERT fundamental statistics | |
|---|---|
| Market cap | US$1.76b |
| Earnings (TTM) | -US$78.68m |
| Revenue (TTM) | US$363.55m |
5.0x
P/S Ratio-23.1x
P/E RatioIs CERT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERT income statement (TTM) | |
|---|---|
| Revenue | US$363.55m |
| Cost of Revenue | US$149.01m |
| Gross Profit | US$214.55m |
| Other Expenses | US$293.23m |
| Earnings | -US$78.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 59.01% |
| Net Profit Margin | -21.64% |
| Debt/Equity Ratio | 28.4% |
How did CERT perform over the long term?
See historical performance and comparison